Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Evaluating the state of the science for adeno-associated virus integration: An integrated perspective

Open access
Sabatino, Denise E., Bushman, Frederic D., Chandler, Randy J., Crystal, Ronald G., Davidson, Beverly L., Dolmetsch, Ricardo, Eggan, Kevin C., Gao, Guangping, Gil-Farina, Irene, Kay, Mark A., McCarty, Douglas M., Montini, Eugenio, Ndu, Adora, Yuan, Jing · 2022 · Molecular Therapy

Abstract

On August 18, 2021, the American Society of Gene and Cell Therapy (ASGCT) hosted a virtual roundtable on adeno-associated virus (AAV) integration, featuring leading experts in preclinical and clinical AAV gene therapy, to further contextualize and understand this phenomenon. Recombinant AAV (rAAV) vectors are used to develop therapies for many conditions given their ability to transduce multiple cell types, resulting in long-term expression of transgenes. Although most rAAV DNA typically remains episomal, some rAAV DNA becomes integrated into genomic DNA at a low frequency, and rAAV insertional mutagenesis has been shown to lead to tumorigenesis in neonatal mice. Currently, the risk of rAAV-mediated oncogenesis in humans is theoretical because no confirmed genotoxic events have been reported to date. However, because insertional mutagenesis has been reported in a small number of murine studies, there is a need to characterize this genotoxicity to inform research, regulatory needs, and patient care. The purpose of this white paper is to review the evidence of rAAV-related host genome integration in animal models and possible risks of insertional mutagenesis in patients. In addition, technical considerations, regulatory guidance, and bioethics are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2022.06.004

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 116

  1. Schmidt, 2008, Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942), J. Virol., 82, 8911, 10.1128/JVI.00672-08 · DOI
  2. Weinmann, 2017, Next-generation AAV vectors for clinical use: an ever-accelerating race, Virus Genes, 53, 707, 10.1007/s11262-017-1502-7 · DOI
  3. Berry, 2016, Cellular transduction mechanisms of adeno-associated viral vectors, Curr. Opin. Virol., 21, 54, 10.1016/j.coviro.2016.08.001 · DOI
  4. Pattali, 2019, AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy, Gene Ther., 26, 287, 10.1038/s41434-019-0085-4 · DOI
  5. Pei, 2020, Development of AAV variants with human hepatocyte tropism and neutralizing antibody escape capacity, Mol. Ther. Methods Clin. Dev., 18, 259, 10.1016/j.omtm.2020.06.003 · DOI
  6. Kantor, 2014, Methods for gene transfer to the central nervous system, Adv. Genet., 87, 125, 10.1016/B978-0-12-800149-3.00003-2 · DOI · Paper page
  7. Kotin, 1990, Site-specific integration by adeno-associated virus, Proc. Natl. Acad. Sci. U S A, 87, 2211, 10.1073/pnas.87.6.2211 · DOI · Paper page
  8. Samulski, 1991, Targeted integration of adeno-associated virus (AAV) into human chromosome 19, EMBO. J., 10, 3941, 10.1002/j.1460-2075.1991.tb04964.x · DOI · Paper page
  9. Hüser, 2010, Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome, PLoS. Pathog., 6, e1000985, 10.1371/journal.ppat.1000985 · DOI
  10. Nowrouzi, 2012, Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver, Mol. Ther., 20, 1177, 10.1038/mt.2012.47 · DOI
  11. Chandler, 2016, Genotoxicity in mice following AAV gene delivery: a safety concern for human gene therapy?, Mol. Ther., 24, 198, 10.1038/mt.2016.17 · DOI
  12. Chandler, 2017, Recombinant adeno-associated viral integration and genotoxicity: insights from animal models, Hum. Gene Ther., 28, 314, 10.1089/hum.2017.009 · DOI · Paper page
  13. Rutledge, 1997, Adeno-associated virus vector integration junctions, J. Virol., 71, 8429, 10.1128/jvi.71.11.8429-8436.1997 · DOI
  14. Yang, 1997, Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro, J. Virol., 71, 9231, 10.1128/jvi.71.12.9231-9247.1997 · DOI · Paper page
  15. Nakai, 1999, Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver, J. Virol., 73, 5438, 10.1128/JVI.73.7.5438-5447.1999 · DOI · Paper page
  16. Miller, 2005, Large-scale analysis of adeno-associated virus vector integration sites in normal human cells, J. Virol., 79, 11434, 10.1128/JVI.79.17.11434-11442.2005 · DOI · Paper page
  17. Donsante, 2001, Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors, Gene Ther., 8, 1343, 10.1038/sj.gt.3301541 · DOI · Paper page
  18. Sands, 1993, A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII, Proc. Natl. Acad. Sci. U S A, 90, 6567, 10.1073/pnas.90.14.6567 · DOI
  19. Daly, 2001, Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer, Gene Ther., 8, 1291, 10.1038/sj.gt.3301420 · DOI
  20. Daly, 1999, Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice, Hum. Gene Ther., 10, 85, 10.1089/10430349950019219 · DOI
  21. Bell, 2005, No evidence for tumorigenesis of AAV vectors in a large-scale study in mice, Mol. Ther., 12, 299, 10.1016/j.ymthe.2005.03.020 · DOI
  22. Bell, 2006, Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver, Mol. Ther., 14, 34, 10.1016/j.ymthe.2006.03.008 · DOI
  23. Zhong, 2013, Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction, Hum. Gene Ther., 24, 520, 10.1089/hum.2012.112 · DOI
  24. Reiss, 2011, Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2, Hum. Mutat., 32, 10, 10.1002/humu.21390 · DOI · Paper page
  25. Embury, 2008, Hepatitis Virus Protein X-Phenylalanine Hydroxylase fusion proteins identified in PKU mice treated with AAV-WPRE vectors, Gene Ther. Mol. Bio., 12, 69
  26. Li, 2011, Assessing the potential for AAV vector genotoxicity in a murine model, Blood, 117, 3311, 10.1182/blood-2010-08-302729 · DOI · Paper page
  27. Wang, 2012, Induction of hepatocellular carcinoma by in vivo gene targeting, Proc. Natl. Acad. Sci. U S A, 109, 11264, 10.1073/pnas.1117032109 · DOI
  28. Rosas, 2012, Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity, Mol. Ther., 20, 2098, 10.1038/mt.2012.197 · DOI
  29. Kao, 2013, Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo, Thromb. Haemost., 110, 244, 10.1160/TH13-02-0154 · DOI
  30. Walia, 2015, Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates, Mol. Ther., 23, 414, 10.1038/mt.2014.240 · DOI
  31. Kang, 2019, Pathogenesis of hepatic tumors following gene therapy in murine and canine models of glycogen storage disease, Mol. Ther. Methods Clin. Dev., 15, 383, 10.1016/j.omtm.2019.10.016 · DOI
  32. Dalwadi, 2021, Liver injury increases the incidence of HCC following AAV gene therapy in mice, Mol. Ther., 29, 680, 10.1016/j.ymthe.2020.10.018 · DOI
  33. Li, 2021, Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for Krabbe disease, Mol. Ther., 29, 691, 10.1016/j.ymthe.2020.12.031 · DOI
  34. Dupuy, 2009, A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice, Cancer Res., 69, 8150, 10.1158/0008-5472.CAN-09-1135 · DOI · Paper page
  35. Riordan, 2013, Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis, PLoS. Genet., 9, e1003441, 10.1371/journal.pgen.1003441 · DOI
  36. Ranzani, 2013, Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer, Nat. Methods, 10, 155, 10.1038/nmeth.2331 · DOI
  37. Hu, 2021, LncRNA MEG8 plays an oncogenic role in hepatocellular carcinoma progression through miR-367-3p/14-3-3ζ/TGFβR1 axis, Neoplasma, 68, 273, 10.4149/neo_2020_200730N785 · doi:10.4149/neo_2020_200730n785
  38. Cataldi, 2010, Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes, J. Virol., 84, 8673, 10.1128/JVI.00641-10 · DOI
  39. Knudson, 1971, Mutation and cancer: statistical study of retinoblastoma, Proc. Natl. Acad. Sci. U S A, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
  40. Colella, 2018, Emerging issues in AAV-mediated in vivo gene therapy, Mol. Ther. Methods Clin. Dev., 8, 87, 10.1016/j.omtm.2017.11.007 · DOI · Paper page
  41. Ferla, 2021, Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors, Mol. Ther. Methods Clin. Dev., 20, 247, 10.1016/j.omtm.2020.11.015 · DOI
  42. Li, 2012, Transcriptome comparison between fetal and adult mouse livers: implications for circadian clock mechanisms, PLoS One, 7, e31292, 10.1371/journal.pone.0031292 · DOI
  43. Kim, 2017, Points to consider in designing and conducting juvenile toxicology studies, Int. J. Toxicol., 36, 325, 10.1177/1091581817699975 · doi:10.1177/1091581817699975
  44. Gauttier, 2013, No tumour-initiating risk associated with scAAV transduction in newborn rat liver, Gene Ther., 20, 779, 10.1038/gt.2013.7 · DOI
  45. Schmidt, 1990, The cytomegalovirus enhancer: a pan-active control element in transgenic mice, Mol. Cell. Biol., 10, 4406
  46. Kay, 1992, Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo, Hum. Gene Ther., 3, 641, 10.1089/hum.1992.3.6-641 · DOI · Paper page
  47. Mattar, 2017, In utero transfer of adeno-associated viral vectors produces long-term factor IX levels in a cynomolgus macaque model, Mol. Ther., 25, 1843, 10.1016/j.ymthe.2017.04.003 · DOI
  48. Spronck, 2020, Assessment of vector integration of AAV5-hFIX in mice and non-human primates indicates No association with tumorigenic risk [Abstract], Res. Pract. Thromb. Haemost., 4
  49. Sullivan, 2021, Rare genomic integrations of AAV5-hFVIII-SQ occur without evidence of clonal activation or gene-specific targeting, Mol. Ther., 29, 425
  50. Mattar, 2011, Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques, Mol. Ther., 19, 1950, 10.1038/mt.2011.107 · DOI
  51. Niemeyer, 2009, Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood, 113, 797, 10.1182/blood-2008-10-181479 · DOI · Paper page
  52. Nguyen, 2021, A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells, Nat. Biotechnol., 39, 47, 10.1038/s41587-020-0741-7 · DOI · Paper page
  53. Batty, 2020, Long-term vector genome outcomes and immunogenicity of AAV FVIII gene transfer in the hemophilia A dog model [abstract], Res. Pract. Thromb. Haemost., 4
  54. Batty, 2020, Frequency, location and nature of AAV vector insertions after long-term follow up of FVIII transgene delivery in a Hemophilia A dog model [abstract], Res. Pract. Thromb. Haemost., 4
  55. Li, 2009, Multi-stage analysis of gene expression and transcription regulation in C57/B6 mouse liver development, Genomics, 93, 235, 10.1016/j.ygeno.2008.10.006 · DOI
  56. Sabatino, 2011, Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors, Mol. Ther., 19, 442, 10.1038/mt.2010.240 · DOI
  57. Venditti, 2021, Safety questions for AAV gene therapy, Nat. Biotechnol., 39, 24, 10.1038/s41587-020-00756-9 · DOI
  58. Arruda, 2004, Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1, Blood, 103, 85, 10.1182/blood-2003-05-1446 · DOI
  59. Nichols, 2015, Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs, Hum. Gene Ther. Clin. Dev., 26, 5, 10.1089/humc.2014.153 · DOI
  60. Dalwadi, 2021, AAV integration in human hepatocytes, Mol. Ther., 29, 2898, 10.1016/j.ymthe.2021.08.031 · DOI
  61. Nathwani, 2018, Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing "empty viral particles" on safety and efficacy of gene transfer, Blood, 132, 491, 10.1182/blood-2018-99-118334 · DOI
  62. George, 2021, Multiyear factor VIII expression after AAV gene transfer for hemophilia A, N. Engl. J. Med., 385, 1961, 10.1056/NEJMoa2104205 · DOI · Paper page
  63. Srivastava, 2017, AAV infection: protection from cancer, Hum. Gene Ther., 28, 323, 10.1089/hum.2016.147 · DOI
  64. Kaeppel, 2013, A largely random AAV integration profile after LPLD gene therapy, Nat. Med., 19, 889, 10.1038/nm.3230 · DOI · Paper page
  65. Pañeda, 2013, Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria, Hum. Gene Ther., 24, 1007, 10.1089/hum.2013.166 · DOI
  66. Schmidt, 2021, Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B [abstract], Res. Pract. Thromb. Haemost., 5
  67. Bushman, 2021, Challenges in estimating numbers of vectors integrated in gene-modified cells using DNA sequence information, Mol. Ther., 29, 3328, 10.1016/j.ymthe.2021.10.022 · doi:10.1016/j.ymthe.2021.10.022
  68. Sherman, 2017, INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes, Mol. Ther. Methods Clin. Dev., 4, 39, 10.1016/j.omtm.2016.11.002 · DOI
  69. Berry, 2017, INSPIIRED: quantification and visualization tools for analyzing integration site distributions, Mol. Ther. Methods Clin. Dev., 4, 17, 10.1016/j.omtm.2016.11.003 · DOI
  70. Locatelli, 2022, Betibeglogene Autotemcel gene therapy for non-β0/β0 genotype β-Thalassemia, N. Engl. J. Med., 386, 415, 10.1056/NEJMoa2113206 · DOI · Paper page
  71. Berry, 2012, Estimating abundances of retroviral insertion sites from DNA fragment length data, J. Bioinform., 28, 755
  72. Tai, 2018, Adeno-associated virus genome population sequencing achieves full vector genome resolution and reveals human-vector chimeras, Mol. Ther. Methods Clin. Dev., 9, 130, 10.1016/j.omtm.2018.02.002 · DOI · Paper page
  73. Zhang, 2021, Flies in the ointment: AAV vector preparations and tumor risk, Mol. Ther., 29, 2637, 10.1016/j.ymthe.2021.08.016 · DOI
  74. Dash, 2019, Differentiating between cancer and normal tissue samples using multi-hit combinations of genetic mutations, Sci. Rep., 9
  75. Guerin, 2020, A novel next-generation sequencing and analysis platform to assess the identity of recombinant adeno-associated viral preparations from viral DNA extracts, Hum. Gene Ther., 31, 664, 10.1089/hum.2019.277 · DOI
  76. Chao, 2006, Abundance-based similarity indices and their estimation when there are unseen species in samples, Biometrics, 62, 361, 10.1111/j.1541-0420.2005.00489.x · DOI · Paper page
  77. Cesana, 2021, Retrieval of vector integration sites from cell-free DNA, Nat. Med., 27, 1458, 10.1038/s41591-021-01389-4 · DOI
  78. Cesana, 2021, Liquid-biopsy-integration-site sequencing allows safety studies and longitudinal monitoring of vector integration sites in LV and AAV-based in-vivo GT applications, Mol. Ther., 29, 129
  79. Bijlani, 2022, The role of recombinant AAV in precise genome editing, Front. Genome Ed., 3, 799722, 10.3389/fgeed.2021.799722 · DOI
  80. Berry, 2006, Selection of target sites for mobile DNA integration in the human genome, PLoS Comput. Biol., 2, e157, 10.1371/journal.pcbi.0020157 · DOI · Paper page
  81. Bushman, 2020, Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones, Mol. Ther., 28, 352, 10.1016/j.ymthe.2019.12.009 · DOI
  82. Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
  83. Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat. Med., 12, 401, 10.1038/nm1393 · DOI · Paper page
  84. Cavazzana, 2019, Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges, Nat. Rev. Drug Discov., 18, 447, 10.1038/s41573-019-0020-9 · DOI · Paper page
  85. Deichmann, 2007, Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy, J. Clin. Invest., 117, 2225, 10.1172/JCI31659 · DOI · Paper page
  86. Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin. Invest., 118, 3143, 10.1172/JCI35798 · DOI · Paper page
  87. Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat. Med., 16, 198, 10.1038/nm.2088 · DOI · Paper page
  88. Klein, 2003, Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice, Blood, 101, 2159, 10.1182/blood-2002-05-1423 · DOI
  89. Lo, 1999, Rapid clearance of fetal DNA from maternal plasma, Am. J. Hum. Genet., 64, 218, 10.1086/302205 · DOI · Paper page
  90. Otsu, 2000, Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy, Mol. Ther., 1, 145, 10.1006/mthe.1999.0020 · DOI
  91. Stein, 2013, From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease, Hum. Gene Ther. Clin. Dev., 24, 86, 10.1089/humc.2013.019 · DOI
  92. Strom, 2003, Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein, Gene Ther., 10, 803, 10.1038/sj.gt.3301950 · DOI
  93. Li, 2002, Murine leukemia induced by retroviral gene marking, Science, 296, 497, 10.1126/science.1068893 · DOI · Paper page
  94. Modlich, 2008, Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16, Leukemia, 22, 1519, 10.1038/leu.2008.118 · DOI
  95. Modlich, 2005, Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis, Blood, 105, 4235, 10.1182/blood-2004-11-4535 · DOI · Paper page
  96. Will, 2007, Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials, Mol. Ther., 15, 782, 10.1038/sj.mt.6300083 · DOI
  97. Modlich, 2006, Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity, Blood, 108, 2545, 10.1182/blood-2005-08-024976 · DOI · Paper page
  98. Modlich, 2009, Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors, Mol. Ther., 17, 1919, 10.1038/mt.2009.179 · DOI · Paper page
  99. Cesana, 2012, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations, J. Clin. Invest., 122, 1667, 10.1172/JCI62189 · DOI
  100. Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat. Biotechnol., 24, 687, 10.1038/nbt1216 · DOI · Paper page
  101. Schwarzer, 2021, Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning, Mol. Ther., 29, 3383, 10.1016/j.ymthe.2021.06.017 · DOI
  102. Aiuti, 2013, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome, Science, 341, 1233151, 10.1126/science.1233151 · DOI · Paper page
  103. Biffi, 2013, Quantitative visualization of DNA G-quadruplex structures in human cells, Nat. Chem., 5, 182, 10.1038/nchem.1548 · DOI · Paper page
  104. Hacein-Bey Abina, 2015, Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome, JAMA, 313, 1550, 10.1001/jama.2015.3253 · DOI · Paper page
  105. Naldini, 2011, Ex vivo gene transfer and correction for cell-based therapies, Nat. Rev. Genet., 12, 301, 10.1038/nrg2985 · DOI · Paper page
  106. Kay, 1992, Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes, Proc. Natl. Acad. Sci. U S A, 89, 89, 10.1073/pnas.89.1.89 · DOI · Paper page
  107. Logan, 2017, Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome, Nat. Genet., 49, 1267, 10.1038/ng.3893 · DOI
  108. El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061 · DOI · Paper page
  109. Verdera, 2020, AAV vector immunogenicity in humans: a long journey to successful gene transfer, Mol. Ther., 28, 723, 10.1016/j.ymthe.2019.12.010 · DOI · Paper page
  110. Nault, 2015, Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas, Nat. Gen., 47, 1187, 10.1038/ng.3389 · DOI · Paper page
  111. La Bella, 2020, Adeno-associated virus in the liver: natural history and consequences in tumour development, Gut, 69, 737, 10.1136/gutjnl-2019-318281 · DOI
  112. Berns, 2015, Adeno-associated virus type 2 and hepatocellular carcinoma?, Hum. Gen. Ther., 26, 779, 10.1089/hum.2015.29014.kib · DOI
  113. Büning, 2015, Adeno-associated vector toxicity-to Be or not to Be?, Mol. Ther., 23, 1673, 10.1038/mt.2015.182 · DOI
  114. Russell, 2015, Adeno-associated virus finds its disease, Nat. Genet., 47, 1104, 10.1038/ng.3407 · DOI
  115. Assaf, 2018, Considerations for preclinical safety assessment of adeno-associated virus gene therapy products, Toxicol. Patho., 46, 1020, 10.1177/0192623318803867 · DOI
  116. Hüser, 2014, Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing, J. Virol., 88, 11253, 10.1128/JVI.01356-14 · DOI

Cited by

See all 212

Metadata

Authors
Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R., Eggan, K. C., Gao, G., Gil-Farina, I., Kay, M. A., McCarty, D. M., Montini, E., Ndu, A., & Yuan, J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2022-08
Volume
30
Issue
8
Pages
2646-2663
ISSN
1525-0016 (ISSN-L)
OpenAlex
W4281664094
Cited by
212
References
34
FWCI
23.02
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluating the state of the science for adeno-associated virus integration: An integrated perspective. https://app.cochat.ai/papers/10.1016/j.ymthe.2022.06.004
The paper
Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R., Eggan, K. C., Gao, G., Gil-Farina, I., Kay, M. A., McCarty, D. M., Montini, E., Ndu, A., & Yuan, J. (2022). Evaluating the state of the science for adeno-associated virus integration: An integrated perspective. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2022.06.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.